United States

Frenova Renal Research expands in the U.S.

Tuesday, August 23, 2016

Frenova Renal Research, a drug and medical device contract clinical development services provider dedicated to renal research, announced its opening of a new office location in downtown Durham, North Carolina, and the expansion of its U.S. field-based staff in New York, Illinois, North Carolina, Florida and Louisiana.

[Read More]

Lilly, AstraZeneca receive FDA Fast Track for Alzheimer’s treatment AZD3293

Tuesday, August 23, 2016

Eli Lilly and AstraZeneca  have received FDA Fast Track designation for the development program in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in phase III clinical trials. The FDA’s Fast Track program is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.

[Read More]

Casebia Therapeutics establishes operations in Cambridge, Massachusetts

Tuesday, August 23, 2016

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, Massachusetts. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness and congenital heart disease. The two parties formally closed the transaction in the first quarter of 2016.

[Read More]

FDA grants Soligenix’s Dusquetide Orphan designation for Macrophage Activation Syndrome

Friday, August 19, 2016

Soligenix, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, has announced that the Office of Orphan Products Development of the FDA has granted Orphan drug designation to the active ingredient dusquetide for treatment of macrophage activation syndrome (MAS). Dusquetide has previously received Orphan drug designation for the treatment of acute radiation syndrome (ARS). 

[Read More]